europabio-logoeuropabio-logoeuropabio-logoeuropabio-logo
  • About us
    • Who we are
      • Governance
      • Staff
      • Vacancies
    • What we do
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Cell & Gene Therapies
      • Medicines For Rare Diseases And Children
      • Regulatory Efficiency
      • Biosimilars & Public Procurement
      • Data & Digital
      • Patient Bio-Forum
    • Industrial Biotechnology Council
      • Food, Feed & Nutrition
      • Circular Bioeconomy
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
  • Activities
    • 25 Years of Innovation
    • EFIB 2022
    • European Biotech Week
  • Events
  • Newsroom
    • News & Publications
    • Newsletter
    • Library
Become a member
✕

1997: First clinical trial with D2E7 (Humira), the first fully human monoclonal antibody approved by the US Food and Drug Administration (FDA)

16/06/2021

Nominated by: BIO Deutschland

Organisations in nomination: BASF, Abbott, AbbVie, Cambridge Antibody Technology (now MedImmune)

Diseases linked to the immune system, such as rheumatoid arthritis were very challenging drug targets, with prolonged treatment often bringing serious side effects and limited effectiveness.

Immunotherapeutics were a high priority for the emerging global biotech sector but it was not until 1997 that a clinical trial for rheumatoid arthritis was undertaken – with D2E7, a fully human monoclonal antibody which acted as a TNF-alpha inhibitor.  TNF (tumour necrosis factor) is part of the inflammatory response seen within arthritis and the TNF inhibitor could, for the first time, open up the prospect to reduce the damaging effects and pain of the disease.

BASF Knoll developed, in collaboration with UK biotech SME Cambridge Antibody Technology, the antibody D2E7 and conducted the clinical trial.  The success of it paved the way for development to market of D2E7, leading to the first fully human monoclonal antibody approved by the US Food and Drug Administration (FDA) in 2002, followed by the EU in 2003.

The advent of TNF-alpha-blockers like Humira has revolutionized the treatment of millions of patients suffering from rheumatoid arthritis and other autoimmune disorders such as Crohn’s disease, colitis ulcerosa and psoriasis.  Disease remission has, since the approval of Humira and related drugs, been a realistic goal for many patients rather than containment or management of symptoms.

Humira is now reported as the highest global drug sales in 2020, at US$19.8bn for AbbVie.  Its pathway from trial by BASF to present day followed acquisition of BASF’s pharma business in 2001 by Abbott, which then split into Abbott and AbbVie in 2013.

References:

  • Top companies and drugs by sales in 2020

Back to the list.

Share
Alexandra Simionca
Alexandra Simionca
EuropaBio-Logo-White

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 2600 biotech companies, 2300 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2023 Europabio. All Rights Reserved. Designed by EYAS
Become a member
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkLegal & Cookies